ASTHMA, ALLERGIC AND IMMUNOLOGIC DISEASES COOP RES CTR

哮喘、过敏和免疫性疾病 COOP RES CTR

基本信息

  • 批准号:
    2470219
  • 负责人:
  • 金额:
    $ 71.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1997
  • 资助国家:
    美国
  • 起止时间:
    1997-09-01 至 2001-08-31
  • 项目状态:
    已结题

项目摘要

Description (adapted from the applicant's Abstract): Cytokines act to modulate the activities of immune and inflammatory cells during all stages of the immune response. The overall goal of the investigators is to understand the mechanisms by which proinflammatory and atopic cytokines modulate the host response to pathogens and environmental antigens. This project focuses particularly on two areas of cytokine regulation as they relate to development and expression of hypersensitivity responses. The first concerns the initial induction of hypersensitivity responses in the epidermis and the role of the proinflammatory cytokines IL-1-beta (IL-1b) and lymphotoxin-alpha (LTa) as mediators of sensitization. The second concerns the mechanism by which Th1 and Th2 cells synergize to establish eosinophilic inflammatory responses in experimental murine airway hypersensitivity. These investigations build on the Principal Investigator's long standing productive investigations of the molecular genetics and cellular physiology of IL-1 and LT, and on his strong clinical interest in asthma and hypersensitivity diseases as Director of the Division of Allergy and Immunology at Washington University. Aim 1 builds on preliminary data indicating that the contact hypersensitivity response is ablated in mice carrying targeted null mutations in the IL-1b and LTa genes and investigates the expression of these cytokines during activation of contact hypersensitivity and how they in turn modulate additional downstream effector mechanisms in the response. It is particularly oriented to understanding the role of epidermal cell apoptosis as a trigger for the release of IL-1b following exposure to sensitizing agents. Aim 2 follows from the applicants initial data using the murine model of ovalbumin (OVA)-induced airway hypersensitivity which have demonstrated that both Th1 and Th2 cells enter the lung early in this hypersensitivity response, and suggest that these cell types synergize in the recruitment of the pathological eosinophilic inflammatory response in the airway. The Th1 and Th2 have traditionally been thought to be counter-regulatory and antagonistic. The applicants propose to investigate the mechanisms by which these two types of cells synergize in the development of the hypersensitivity response. Program Interactions: These Aims will be facilitated by sustained interactions with other members of the AAIDCRC. In particular, Dr. Murphy (Project 2) is an internationally recognized scholar in the field of Th1 and Th2 phenotype development. His experience in this area and the many reagents and methods he has developed will prove phenotype development. His experience in this area and the many reagents and methods he has developed will prove exceptionally useful for Aim 2. Dr. Unanue (Project 3) and Dr. Chaplin have worked together for nearly 10 years studying the physiology of IL-1, and Dr. Unanue's experience in the use of neutralizing anti-cytokine antibodies to study physiological functions in vivo will strengthen the application of these types of experiments. The addition of Dr. Yokoyama (Project 4) to the AAIDCRC will support efforts to determine the role of NK cells as regulators of these hypersensitivity responses.
描述(改编自申请人摘要):细胞因子作用于

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David D Chaplin其他文献

Role of inflammation in recruitment of Th2 lymphocytes to the lung
  • DOI:
    10.1016/s0091-6749(02)81348-3
  • 发表时间:
    2002-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    David D Chaplin;Robin Stephens
  • 通讯作者:
    Robin Stephens
Distinct characteristics of T cell rolling and adhesion in splenic versus lymph node vessels
  • DOI:
    10.1016/s0091-6749(02)82116-9
  • 发表时间:
    2002-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Mitchell H Grayson;Michael J Holtzman;David D Chaplin
  • 通讯作者:
    David D Chaplin

David D Chaplin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David D Chaplin', 18)}}的其他基金

ACQUISITION OF A 200 KV CRYO-ELECTRON MICROSCOPE: INFECTIOUS DISEASE
购买 200 KV 冷冻电子显微镜:传染病
  • 批准号:
    7166293
  • 财政年份:
    2005
  • 资助金额:
    $ 71.4万
  • 项目类别:
Acquisition of a 200 kV Cryo-Electron Microscope
购置 200 kV 冷冻电子显微镜
  • 批准号:
    6803864
  • 财政年份:
    2005
  • 资助金额:
    $ 71.4万
  • 项目类别:
IMMUNOREGULATION AT EPITHELIAL BARRIERS
上皮屏障的免疫调节
  • 批准号:
    6344620
  • 财政年份:
    2000
  • 资助金额:
    $ 71.4万
  • 项目类别:
IMMUNOREGULATION AT EPITHELIAL BARRIERS
上皮屏障的免疫调节
  • 批准号:
    6201171
  • 财政年份:
    1999
  • 资助金额:
    $ 71.4万
  • 项目类别:
IMMUNOREGULATION AT EPITHELIAL BARRIERS
上皮屏障的免疫调节
  • 批准号:
    6099662
  • 财政年份:
    1998
  • 资助金额:
    $ 71.4万
  • 项目类别:
ASTHMA, ALLERGIC AND IMMUNOLOGIC DISEASES COOP RES CTR
哮喘、过敏和免疫性疾病 COOP RES CTR
  • 批准号:
    2672245
  • 财政年份:
    1997
  • 资助金额:
    $ 71.4万
  • 项目类别:
ASTHMA, ALLERGIC AND IMMUNOLOGIC DISEASES COOP RES CTR
哮喘、过敏和免疫性疾病 COOP RES CTR
  • 批准号:
    6170269
  • 财政年份:
    1997
  • 资助金额:
    $ 71.4万
  • 项目类别:
IMMUNOREGULATION AT EPITHELIAL BARRIERS
上皮屏障的免疫调节
  • 批准号:
    6235134
  • 财政年份:
    1997
  • 资助金额:
    $ 71.4万
  • 项目类别:
ASTHMA, ALLERGIC AND IMMUNOLOGIC DISEASES COOP RES CTR
哮喘、过敏和免疫性疾病 COOP RES CTR
  • 批准号:
    2886860
  • 财政年份:
    1997
  • 资助金额:
    $ 71.4万
  • 项目类别:
ASTHMA, ALLERGIC AND IMMUNOLOGIC DISEASES COOP RES CTR
哮喘、过敏和免疫性疾病 COOP RES CTR
  • 批准号:
    2069732
  • 财政年份:
    1993
  • 资助金额:
    $ 71.4万
  • 项目类别:

相似海外基金

Development of platform for non-invasive, rapid, and simple analysis of cytokine secretion from single cells
开发非侵入、快速、简单分析单细胞细胞因子分泌的平台
  • 批准号:
    23H01824
  • 财政年份:
    2023
  • 资助金额:
    $ 71.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Therapeutic approach to confer an anti-tumorigenic role of IL-6 to the pro-tumorigenic cytokine in effector T cells
赋予效应T细胞中促肿瘤细胞因子IL-6抗肿瘤作用的治疗方法
  • 批准号:
    23K06723
  • 财政年份:
    2023
  • 资助金额:
    $ 71.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Diversity of haematopoietic cytokine receptor activation exploring with marine probes
用海洋探针探索造血细胞因子受体激活的多样性
  • 批准号:
    23K14019
  • 财政年份:
    2023
  • 资助金额:
    $ 71.4万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A point-of-care salivary cytokine test for early detection of oral cancer
用于早期发现口腔癌的即时唾液细胞因子检测
  • 批准号:
    10760626
  • 财政年份:
    2023
  • 资助金额:
    $ 71.4万
  • 项目类别:
Development of Coccidioides Cytokine Release Assay
球孢子菌细胞因子释放测定的发展
  • 批准号:
    10760131
  • 财政年份:
    2023
  • 资助金额:
    $ 71.4万
  • 项目类别:
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
  • 批准号:
    10648387
  • 财政年份:
    2023
  • 资助金额:
    $ 71.4万
  • 项目类别:
FOXA1 regulates cytokine signaling and immune landscape in prostate cancer through ARID1A
FOXA1 通过 ARID1A 调节前列腺癌中的细胞因子信号传导和免疫景观
  • 批准号:
    10681898
  • 财政年份:
    2023
  • 资助金额:
    $ 71.4万
  • 项目类别:
Cytokine Regulation of Secondary Neural Progenitors
次级神经祖细胞的细胞因子调节
  • 批准号:
    10752901
  • 财政年份:
    2023
  • 资助金额:
    $ 71.4万
  • 项目类别:
Generating a novel conditional knockout mouse for a super-enhancer that controls cytokine responsiveness
生成一种新型条件敲除小鼠,用于控制细胞因子反应的超级增强子
  • 批准号:
    10740932
  • 财政年份:
    2023
  • 资助金额:
    $ 71.4万
  • 项目类别:
Cytokine receptor common beta chain alterations in mediastinal lymphomas
纵隔淋巴瘤细胞因子受体常见β链改变
  • 批准号:
    489197
  • 财政年份:
    2023
  • 资助金额:
    $ 71.4万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了